Clinical Research Directory

Inclusion Criteria: * Male or female aged ≥18 years * Received curative-intent chemotherapy (i.e., paclitaxel, docetaxel, nab-paclitaxel, carboplatin, oxaliplatin, vinorelbine, ixabepilone, or vincristine) ≥3 months prior to the start of EA treatment * Persistent Grade ≥2 peripheral neuropathy in the fingers or toes according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 * Eastern Cooperative Oncology Group performance status of ≤2 (see Section 13.3) * Willing and able to provide written informed consent for the study. Exclusion Criteria: * Documented medical history of neuropathy resulting from nerve compression (e.g., carpal tunnel syndrome, radiculopathy, or spinal stenosis) * Severe coagulopathy or bleeding disorder, per the treating physician's discretion * Presence of cellulitis or other skin infection or condition that would preclude placement of acupuncture needles into the hands or feet * Diabetes unless Hgb A1c \<7.5% * Unstable cardiac disease * Pacemaker * Metal plates * Known psychiatric disorder that would interfere with cooperation with the requirements of the study * Pregnant